Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCLEC.syn1 CAR T Cells in Relapsed or Refractory Acute Myeloid Leukemia
NCT05748197Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADCLEC.syn1 CAR T cells in acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
ADCLEC.syn1 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05748197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748197.